List of Tables
Table 1. Direct-acting Antiviral Drugs Market Trends
Table 2. Direct-acting Antiviral Drugs Market Drivers & Opportunity
Table 3. Direct-acting Antiviral Drugs Market Challenges
Table 4. Direct-acting Antiviral Drugs Market Restraints
Table 5. Global Direct-acting Antiviral Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Direct-acting Antiviral Drugs Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Direct-acting Antiviral Drugs Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Direct-acting Antiviral Drugs Product Type
Table 9. Key Companies Time to Begin Mass Production of Direct-acting Antiviral Drugs
Table 10. Global Direct-acting Antiviral Drugs Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Direct-acting Antiviral Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Direct-acting Antiviral Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Direct-acting Antiviral Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Direct-acting Antiviral Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Direct-acting Antiviral Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Direct-acting Antiviral Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Direct-acting Antiviral Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Direct-acting Antiviral Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Direct-acting Antiviral Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Direct-acting Antiviral Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Direct-acting Antiviral Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Direct-acting Antiviral Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Direct-acting Antiviral Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Direct-acting Antiviral Drugs Sales Value by Region (2019-2024) & (%)
Table 27. Global Direct-acting Antiviral Drugs Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Direct-acting Antiviral Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Direct-acting Antiviral Drugs Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Direct-acting Antiviral Drugs Sales Value, (2025-2030) & (US$ Million)
Table 31. AbbVie Inc. Basic Information List
Table 32. AbbVie Inc. Description and Business Overview
Table 33. AbbVie Inc. Direct-acting Antiviral Drugs Products, Services and Solutions
Table 34. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of AbbVie Inc. (2019-2024)
Table 35. AbbVie Inc. Recent Developments
Table 36. GSK Basic Information List
Table 37. GSK Description and Business Overview
Table 38. GSK Direct-acting Antiviral Drugs Products, Services and Solutions
Table 39. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of GSK (2019-2024)
Table 40. GSK Recent Developments
Table 41. Boehringer Ingelheim Basic Information List
Table 42. Boehringer Ingelheim Description and Business Overview
Table 43. Boehringer Ingelheim Direct-acting Antiviral Drugs Products, Services and Solutions
Table 44. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Boehringer Ingelheim (2019-2024)
Table 45. Boehringer Ingelheim Recent Developments
Table 46. Merck Basic Information List
Table 47. Merck Description and Business Overview
Table 48. Merck Direct-acting Antiviral Drugs Products, Services and Solutions
Table 49. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Merck (2019-2024)
Table 50. Merck Recent Developments
Table 51. Novartis Basic Information List
Table 52. Novartis Description and Business Overview
Table 53. Novartis Direct-acting Antiviral Drugs Products, Services and Solutions
Table 54. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Novartis (2019-2024)
Table 55. Novartis Recent Developments
Table 56. Beximco Pharmaceuticals Basic Information List
Table 57. Beximco Pharmaceuticals Description and Business Overview
Table 58. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Products, Services and Solutions
Table 59. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Beximco Pharmaceuticals (2019-2024)
Table 60. Beximco Pharmaceuticals Recent Developments
Table 61. Roche Basic Information List
Table 62. Roche Description and Business Overview
Table 63. Roche Direct-acting Antiviral Drugs Products, Services and Solutions
Table 64. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Roche (2019-2024)
Table 65. Roche Recent Developments
Table 66. Bristol-Myers Squibb Company Basic Information List
Table 67. Bristol-Myers Squibb Company Description and Business Overview
Table 68. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Products, Services and Solutions
Table 69. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Bristol-Myers Squibb Company (2019-2024)
Table 70. Bristol-Myers Squibb Company Recent Developments
Table 71. Gilead Sciences Basic Information List
Table 72. Gilead Sciences Description and Business Overview
Table 73. Gilead Sciences Direct-acting Antiviral Drugs Products, Services and Solutions
Table 74. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Gilead Sciences (2019-2024)
Table 75. Gilead Sciences Recent Developments
Table 76. Janssen (Johnson & Johnson) Basic Information List
Table 77. Janssen (Johnson & Johnson) Description and Business Overview
Table 78. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Products, Services and Solutions
Table 79. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Janssen (Johnson & Johnson) (2019-2024)
Table 80. Janssen (Johnson & Johnson) Recent Developments
Table 81. Vertex Pharmaceuticals Basic Information List
Table 82. Vertex Pharmaceuticals Description and Business Overview
Table 83. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Products, Services and Solutions
Table 84. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Vertex Pharmaceuticals (2019-2024)
Table 85. Vertex Pharmaceuticals Recent Developments
Table 86. Natco Pharma Basic Information List
Table 87. Natco Pharma Description and Business Overview
Table 88. Natco Pharma Direct-acting Antiviral Drugs Products, Services and Solutions
Table 89. Revenue (US$ Million) in Direct-acting Antiviral Drugs Business of Natco Pharma (2019-2024)
Table 90. Natco Pharma Recent Developments
Table 91. Key Raw Materials Lists
Table 92. Raw Materials Key Suppliers Lists
Table 93. Direct-acting Antiviral Drugs Downstream Customers
Table 94. Direct-acting Antiviral Drugs Distributors List
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
Table 98. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Direct-acting Antiviral Drugs Product Picture
Figure 2. Global Direct-acting Antiviral Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Direct-acting Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. Direct-acting Antiviral Drugs Report Years Considered
Figure 5. Global Direct-acting Antiviral Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Direct-acting Antiviral Drugs Revenue in 2023
Figure 7. Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. NS3/4A Protease Inhibitors Picture
Figure 9. Nucleoside and Nucleotide NS5B Polymerase Inhibitors Picture
Figure 10. NS5A Inhibitors Picture
Figure 11. Non-Nucleoside NS5B Polymerase Inhibitors Picture
Figure 12. Global Direct-acting Antiviral Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Direct-acting Antiviral Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Hospitals
Figure 15. Product Picture of Clinics
Figure 16. Product Picture of Ambulatory Surgical Centers
Figure 17. Product Picture of Pharmacies
Figure 18. Product Picture of Others
Figure 19. Global Direct-acting Antiviral Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global Direct-acting Antiviral Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 21. North America Direct-acting Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 22. North America Direct-acting Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 23. Europe Direct-acting Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 24. Europe Direct-acting Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 25. Asia Pacific Direct-acting Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 26. Asia Pacific Direct-acting Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 27. South America Direct-acting Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 28. South America Direct-acting Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 29. Middle East & Africa Direct-acting Antiviral Drugs Sales Value (2019-2030) & (US$ Million)
Figure 30. Middle East & Africa Direct-acting Antiviral Drugs Sales Value by Country (%), 2023 VS 2030
Figure 31. Key Countries/Regions Direct-acting Antiviral Drugs Sales Value (%), (2019-2030)
Figure 32. United States Direct-acting Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 33. United States Direct-acting Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 34. United States Direct-acting Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 35. Europe Direct-acting Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 36. Europe Direct-acting Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 37. Europe Direct-acting Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 38. China Direct-acting Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 39. China Direct-acting Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 40. China Direct-acting Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 41. Japan Direct-acting Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 42. Japan Direct-acting Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 43. Japan Direct-acting Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 44. South Korea Direct-acting Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 45. South Korea Direct-acting Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 46. South Korea Direct-acting Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 47. Southeast Asia Direct-acting Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 48. Southeast Asia Direct-acting Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 49. Southeast Asia Direct-acting Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 50. India Direct-acting Antiviral Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 51. India Direct-acting Antiviral Drugs Sales Value by Type (%), 2023 VS 2030
Figure 52. India Direct-acting Antiviral Drugs Sales Value by Application (%), 2023 VS 2030
Figure 53. Direct-acting Antiviral Drugs Industrial Chain
Figure 54. Direct-acting Antiviral Drugs Manufacturing Cost Structure
Figure 55. Channels of Distribution (Direct Sales, and Distribution)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
